IJBPAS, July, 2026, 15(7): 3189-3199

ISSN: 2277–4998

International Journal of Biology, Pharmacy and Allied Sciences (IJBPAS)

'A Bridge Between Laboratory and Reader'

www.ijbpas.com

PHARMACOKINETIC AND PHARMACODYNAMIC MODELLING USING ARTIFICIAL INTELLIGENCE AND DEEP LEARNING

VASANTHA G[*1], SAI POOJITHA M[1], JASVITHA M[1], VINEELA N[2], SRINIVASA RAO Y[3]

1, 2[*]: Department of Pharmacology, Vignan Institute of Pharmaceutical Technology(A), Duvvada, Visakhapatnam, 530049, Andhra Pradesh, India

3: Professor, Principal, Department of Pharmaceutical Analysis, Vignan Institute of Pharmaceutical Technology(A), Duvvada, Visakhapatnam, 530049, Andhra Pradesh, India

***Corresponding Author: Dr. G. Vasantha: E Mail: drvasanthaniper@gmail.com**

Received 5th June 2025; Revised 18th July 2025; Accepted 8th Oct. 2025; Available online 1st July 2026

https://doi.org/10.31032/IJBPAS/2026/15.7.10306

ABSTRACT

The discipline of pharmacokinetics delineates the absorption, distribution, metabolism, and excretion (ADME) of pharmaceutical agents within the corporeal framework, whereas pharmacodynamics elucidates the biological consequences and mechanisms of action of these substances. The integration of pharmacokinetic-pharmacodynamic (PK/PD) modelling has become increasingly pivotal in contemporary drug development, facilitating the prognostication of therapeutic outcomes across heterogeneous patient populations and pathological milieux. With the emergence of synthetic intellect and advanced hierarchical learning the capacity to analyse voluminous biomedical datasets has been augmented, enabling more robust structure-activity relationship modelling, target identification, virtual screening. These computational paradigms not only expedite the discovery process but also enhance the precision of dosage regimen design and toxicity prediction. However, the efficacious deployment of these methodologies necessitates scrupulous validation to mitigate the perils of bias and overestimation of predictive prowess. The present treatise underscores the significance of hybrid modelling approaches, which amalgamate linear and nonlinear techniques, and emphasizes the imperative of model interpretability and transparency in high-stakes pharmacological decision-making.

Keywords: Artificial intelligence, Pharmacokinetics, Pharmacodynamics, Deep Learning, Personalized Medicine

INTRODUCTION

Overview of PK/PD modelling

Pharmacokinetics (PK) and pharmacodynamics (PD) constitute fundamental pillars in the advancement of pharmaceutical research and the paradigm of precision medicine. PK provides a comprehensive elucidation of the temporal and spatial dynamics governing a therapeutic agent's journey through the biological system, encompassing its assimilation, systemic distribution, biotransformation and renal clearance (ADME). PD, in contrast, seeks to delineate the biological repercussions of a given pharmacological entity, probing its molecular mechanisms of action. Precision Medicine (PM) integrates PK/PD modelling frameworks to tailor therapeutic interventions, ensuring optimal drug efficacy by accommodating phenotypic and genotypic variances among individuals. The interdisciplinary field of pharmacokinetic-pharmacodynamic (PK/PD) modelling has undergone a profound evolution, progressing from the rudimentary dose-response correlation to increasingly complex, mechanism-driven models that encompass multifactorial interactions **[1]**. Crucial Pharmacodynamic Inter-relationships include Fundamental Conceptual Models that establish associations between pharmacological dosage or plasma concentrations and biological effects, alongside BioPhase distribution frameworks, with particular emphasis on effect compartment that characterize cellular trafficking and signal transduction systems **[2]**.

Significance of Pharmacokinetic/ Pharmacodynamic Modelling in Pharmaceutical Development

Pharmacokinetic/Pharmacodynamic modelling will assume an increasingly integral role in drug development by elucidating critical in vivo properties of therapeutic agents. This approach allows for understanding and predicting how long a drug will work under different physiological and pathological conditions. Recent findings will offer new insights into the complexities of diseases and the discovery of multiple targets for treatment. This will lead to new chances for drug combinations, which can only be developed sensibly by using dynamical systems-based PK/PD models **[3]**.

The Emergence of Artificial Intelligence and Deep Learning in Biomedical Sciences

Artificial Intelligence and Deep Learning have increasingly emerged as indispensable methodologies within the biomedical research domain. They are now widely used inanalyzing medical images and genetic sequences that can provide valuable insights for diagnosis, treatment, and prevention **[4]**.

Fundamentals of pk/pd modelling

Pharmacokinetics is commonly characterized as the dynamic process through which the organism interacts with a pharmacological agent**,** encompassing the absorption**,** distribution**,** biotransformation**,** and elimination (ADME) of the drug. Understanding these processes is crucial for determining the right dosage, method of delivery, and frequency of a medication **[5]**. Preclinical pharmacokinetic studies focus on In-vitro and In-vivo methodologies. Clinical pharmacokinetic studies are reviewed throughout different phases of clinical trials. This includes dose escalation studies, assessments of drug-drug interactions, and population pharmacokinetics. The discussion pays special attention to pharmacokinetic differences in children, the elderly, and those with kidney or liver impairments. It covers oral, parenteral, and controlled-release formulations, along with the importance of physicochemical properties, prodrugs, and bioconversion **[6]**. Pharmacodynamics refers to the investigation of the biological effects and mechanisms of action through which a pharmacological agent influences the physiological processes of the organism. The dose-response relationship is a fundamental concept in pharmacodynamics. Important terms such as *potency*, which denotes the requisite pharmacological quantity to elicit a specified response, and therapeutic efficacy. In addition, the *therapeutic index* reflects the balance between the beneficial effects of a drug and its potential side effects, making it a key factor in assessing drug safety **[7]**.



Figure 1: Traditional pharmacokinetic approaches

Limitations of conventional methods

PBPK modelling requires detailed Information regarding the physiological, biochemical, and physicochemical mechanisms operating in biological systems across different age ranges or under specific physiological and pathological states is crucial. While several biological processes have been extensively delineated. The Shortcomings such as the abundance of

transporters or Absorptive pharmacokinetics in early-life stages, can prevent the modelling approach from accurately describing the pharmacokinetic behaviour of certain drugs in these populations. Lastly, researchers and users of this modelling system should grasp the physiological and pharmacodynamic rationale underlying the model. They should further recognize that PBPK modelling, while potentially beneficial and versatile, does not offer a definitive solution and that there are still few examples that demonstrate its effectiveness in clinical practice compared to its theoretical applications. **[8]**

Role of AI in drug modelling

AI has evolved into a fundamental asset as a strong tool that uses human-like knowledge and offers quick solutions to tough problems. Ongoing innovations in AI frameworks and deep neural networks provide a chance to change how we discover formulate and evaluate pharmaceutical dosage forms through the application of AI-driven algorithms to analyse large amounts by leveraging biological datasets, including proteomics and genomics, Investigators can pinpoint disease-related molecular targets and predict their interactions with potential Investigational drugs. **[9]**



Figure 2: AI into Biologicals

Within the pharmaceutical industry, many COVID-19 vaccines became unusable during the pandemic due to challenges with maintaining the controlled-temperature Logistical network. The chief driver of supply chain disruptions Originating from late responsiveness is the absence of innovation and the prevalence of imprecise demand forecasting within business operations. Such disruptions significantly

undermine customer satisfaction, erode corporate reputation, and diminish potential profit margins **[10, 11]**. Artificial Intelligence is emerging as a catalyst for innovation in supply chain management in the pharmaceutical industry **(Figure 3)**. By unifying decades of AI research, it enables effective solutions to complex logistical challenges. The study also outlines future research directions to enhance decision-support systems **[12, 13]**.

Figure 3: Supply chain operations

AI for Drug Discovery

Artificial intelligence is increasingly influencing various stages of drug discovery, including predictive toxicology, drug repurposing, and the optimization of drug candidates. It also supports de novo drug design by enabling the generation of novel molecular structures with desired properties. Through structure–activity relationship (SAR) modelling and virtual screening, AI enhances the identification of promising compounds. Additionally, it contributes to early-stage efforts such as target identification, thereby streamlining the entire discovery pipeline **[14]**.

AI for Drug Delivery

Artificial intelligence for the formulation and optimization of oral solid pharmaceutical dosage systems. The integration of artificial intelligence in the development and optimization of 3D-printed drug delivery platforms, Application of Artificial Intelligence in Identifying Tablet Defects, Prediction of Physicochemical Stability, Dissolution Rate Predictions, Nanomedicine, development and optimization of therapeutic products,

Medical Devices, Pharmacokinetics and Pharmacodynamics "With greater speed, reduced expenditure, and enhanced precision **[15, 16]**.

What is AI in healthcare and pharmacology?

AI is now embedded across the entire pharmacological landscape from early drug discovery to real-world data analysis. Techniques range from unsupervised clustering to identify candidate compounds or patient subgroups, to supervised learning models that enhance therapeutic drug monitoring **[17]**. Artificial intelligence is poised to influence multiple domains within "Clinical pharmacology encompasses domains such as, individualized therapy, pharmacogenomics, drug discovery, clinical development, safety surveillance, and clinical toxicology." the implementation of AI must undergo rigorous and systematic evaluation to ensure its integration enhances clinical outcomes safely, effectively, and unbiased manner **[18]**.

Deep learning techniques in pharmacokinetic and pharmacodynamic modelling

Deep learning is increasingly transforming multiple facets of scientific research and technological innovation. It has been adeptly applied in biomolecular modelling and structural genomics to predict tertiary protein structures based on amino acid sequences, including intrinsically disordered proteins that lack stable three-dimensional conformations. Such advancements underscore the potential of deep learning as an indispensable tool in the rational design of next-generation therapeutics. In addition, deep learning architectures have been effectively utilized to forecast drug–target interactions, simulate molecular reactivity, and evaluate compound toxicity **[19]**.

Deep learning algorithms have been operationalized across a broad spectrum of pharmaceutical discovery paradigms, including peptide biosynthesis, structure-guided in silico screening, ligand-centric virtual interrogation, toxicity prognostication, pharmacophoric abstraction, quantitative structure–activity correlation, therapeutic repurposing, Poly pharmacological profiling, and elucidation of physicochemical bioactivity **[20]**. The meantime mid-range effects 20 - 80% see a linear drop which is despite an exponential change in concentration. This information is useful in the design of dose regimens based on PK/PD principles **[21]**. Neural PK/PD models that which combine deep learning with ODE solvers are putting forth very accurate predictions of drug concentration and patient response **[22]**. In some cases, we see that post hoc justifications of black box models to be quite often misleading, instead what we put forth is a focus on the

development of very transparent models **[23]**.

Applications of Artificial Intelligence and deep learning in pharmacokinetics and pharmacodynamics

Artificial Intelligence is a Cross-disciplinary domain which combines mathematics, psychology and computer science **[24]**. AI are growing in their application within drug discovery for better DMPK studies which we see supported by the greater available data and computing power **[25]**. Clinical outcome prediction is an integral part of drug discovery development. 52% of drugs fail due to lack of efficacy. Pharmacodynamic models help optimize screening by predicting drug action on bodily systems, which aids in refining candidate selection and accelerating development timelines **[26]**.

Case studies and recent advances in pharmacokinetic and pharmacodynamic modelling using artificial intelligence and deep learning

Case study 1-(Mechanistic PK/PD Modelling as a Strategic Tool in Drug Development)

1. The modelling aimed to evolve from initial observational PK/PD models to a refined mechanistic framework.
2. Stage I validated the PK assay and used an empirical model to confirm measurement of biologically active drug.
3. Stage II used patient data to build an empirical PK/PD model, guiding fixed-dose decisions and dose escalation in study 5.
4. Stage III introduced a mechanistic model to bridge healthy volunteer and patient data, clarifying clearance mechanisms.
5. Stage IV applied the mechanistic model to a large efficacy study, confirming consistency with earlier data.
6. Data included drug concentrations, CD11b receptor occupancy, and neutrophil counts from 5 clinical studies.
7. The model development used NONMEM software and incorporated data from over 1,200 subjects.
8. Early empirical models informed study design, while mechanistic models enabled cross-population PK/PD integration.
9. Overall, modelling supported decision-making, dose selection, and ensured consistency across development stages **[27]**.

Case study 2-(A PBPK Modelling Workflow to Inform Paediatric Drug Development)

(A Case Study Using Lorazepam)

1. The study aimed to demonstrate a paediatric PBPK modelling

workflow following FDA recommendations.

2. Lorazepam, a centrally acting benzodiazepine Administered across both adult and paediatric populations, was chosen as the case drug.
3. A population PBPK model was developed using PK-Sim v4.2®, incorporating age-dependent physiological changes.
4. The model scaled tissue composition, Plasma protein affinity and the developmental progression of elimination pathways by age.
5. Paediatric dose requirements (mg/kg) were simulated to match adult exposure levels across ages 0–18.
6. Model accuracy was evaluated using average-fold error (AFE) in 63 children and fold error (FE) for CL and Vss in 15 children.
7. Young children (1–3 years) required higher weight-adjusted doses than adults.
8. 73% of predicted concentrations were within 1.5-fold and 92% within 2-fold of observed values.
9. Clearance predictions were accurate in 60% (within 1.5 FE) and 80% (within 2 FE); Vss predictions were more accurate.
10. The model effectively predicted lorazepam PK across paediatric ages, supporting age-based dose selection **[28]**.

CONCLUSION

In summation, the confluence of pharmacokinetic and pharmacodynamic modelling with artificial intelligence has engendered a paradigm shift in the pharmaceutical landscape. The utilization of sophisticated algorithms and deep learning architectures has facilitated the discernment of intricate patterns within pharmacological data, thereby refining the accuracy of drug effect prognostication and optimizing therapeutic regimens. Notwithstanding these advancements, challenges pertaining to data quality, model robustness, and interpretability persist, necessitating the adoption of rigorous validation protocols and hybrid modelling strategies. The integration of AI into PK/PD modelling not only augments the efficiency of drug development but also signals a shift toward precision medicine, where treatment modalities are tailored to the specific needs of each patient to individual patient characteristics. As the field continues to evolve, it is incumbent upon researchers to prioritize transparency, ethical considerations, and the harmonization of computational and experimental methodologies to achieve the complete potential of these transformative technologies.

REFERENCES

[1] Ray A, AI-Driven PK/PD Modeling: Generative AI, LLMs, and LangChain for Precision Medicine, Compassionate AI, 1(3), 2025, 48-50.

[2] Csajka C, Verotta D, Pharmacokinetic–pharmacodynamic modelling: history and perspectives, Journal of pharmacokinetics and pharmacodynamics, 33(3), 2006, 227-79.

[3] Breimer DD, PK/PD modelling and beyond: impact on drug development, Pharmaceutical research, 25(12), 2008, 2720-2.

[4] Khan WH, Khan MS, Khan N, Ahmad A, Siddiqui ZI, Singh RB, Malik MZ, Artificial intelligence, machine learning and deep learning in biomedical fields: A prospect in improvising medical healthcare systems, In Artificial Intelligence in Biomedical and Modern Healthcare Informatics Academic Press, 2025, 55-68.

[5] Chloe L, Pharmacokinetics and pharmacodynamics: Essential principles in clinical drug development, J Clin Bioanal Chem, 7(4), 2023, 161.

[6] Dewangan MT, Bhoyar MN, pharmacokinetic considerations in drug development: a review, South African Gastroenterology Review, 22(3), 2024, 169-86.

[7] Robinson S, Pharmacokinetics and pharmacodynamics: The unraveling mechanisms of drug action, J Pharmacol Ther Res, 7(4), 2023, 154.

[8] Khalil F, Läer S, Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development, BioMed Research International, 2011(1), 2011, 907461.

[9] Vora LK, Gholap AD, Jetha K, Thakur RR, Solanki HK, Chavda VP, Artificial intelligence in pharmaceutical technology and drug delivery design, Pharmaceutics, 15(7), 2023, 1916.

[10] Golan MS, Trump BD, Cegan JC, Linkov I, The vaccine supply chain: a call for resilience analytics to support COVID-19 vaccine production and distribution, InCOVID-19: systemic risk and resilience, Springer International Publishing, 2021, 389-437.

[11] Vora LK, Gholap AD, Jetha K, Thakur RRS, Solanki HK, Chavda VP, Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design, Pharmaceutics, 15(7), 2023, 1916

[12] Badejo O, Ierapetritou M, Enhancing pharmaceutical supply chain resilience: A multi-objective study with disruption management, Computers & Chemical Engineering, 188, 2024, 108769.

[13] Sharma, R, Shishodia, A, Gunasekaran, A, Min, H. Munim, Z.H, The Role of Artificial Intelligence in Supply Chain Management: Mapping the Territory. Int., J.Prod. Res, 60, 2022, 7527–7550.

[14] Mak KK, Pichika MR, Artificial intelligence in drug development: present status and future prospects, Drug discovery today, 24(3), 2019, 773-80.

[15] Alsultan, A., Alghamdi, W.A., Alghamdi, J. Alharbi, A.F. Aljutayli, A. Albassam, A., Almazroo, O, Alqahtani, S, Clinical Pharmacology Applications in Clinical Drug Development and Clinical Care: A Focus on Saudi Arabia, Saudi Pharm. J, 28, 2020, 1217–1227.

[16] Keutzer L, You H, Farnoud A, Nyberg J, Wicha SG, Maher-Edwards G, Vlasakakis G, Moghaddam GK, Svensson EM, Menden MP, Simonsson US, Machine learning and pharmacometrics for prediction of pharmacokinetic data: differences, similarities and challenges illustrated with rifampicin, Pharmaceutics, 14(8), 2022, 1530.

[17] Van der Lee M, Swen JJ, Artificial intelligence in pharmacology research and practice, Clinical and Translational Science, 16(1), 2023, 31-6.

[18] Ryan DK, Maclean RH, Balston A, Scourfield A, Shah AD, Ross J, Artificial intelligence and machine learning for clinical pharmacology, British Journal of Clinical Pharmacology, 90(3), 2024, 629-39.

[19] Aliper A, Plis S, Artemov A, Ulloa A, Mamoshina P, Zhavoronkov A, Deep learning applications for predicting pharmacological properties of drugs and drug repurposing using transcriptomic data, Molecular pharmaceutics, 13(7), 2016, 2524-30.

[20] Gupta R, Srivastava D, Sahu M, Tiwari S, Ambasta RK, Kumar P, Artificial intelligence to deep learning: machine intelligence approach for drug discovery, Molecular diversity, 25(3), 2021, 1315-60.

[21] Holford NH, Sheiner LB, Understanding the dose-effect relationship: clinical application of

pharmacokinetic-pharmacodynamic models, Clinical pharmacokinetics, 6(6), 1981, 429-53.

[22] Lu J, Bender B, Jin JY, Guan Y, Deep learning prediction of patient response timecourse from early data via neural-pharmacokinetic/pharmacodynamic modelling, Nature machine intelligence, 3(8), 2021, 696-704.

[23] Lisboa PJ, Saralajew S, Vellido A, Fernández-Domenech R, Villmann T, The coming of age of interpretable and explainable machine learning models, Neurocomputing, 535, 2023, 25-39.

[24] Jaboob A, Durrah O, Chakir A, Artificial intelligence: An overview, Engineering applications of artificial intelligence, 2024, 3-22.

[25] Wright MR, Opportunities and considerations in the application of artificial intelligence to pharmacokinetic prediction, In Artificial Intelligence in Drug Design, New York, NY: Springer US, 2021, 461-482.

[26] Wu K, Li X, Zhou Z, Zhao Y, Su M, Cheng Z, Wu X, Huang Z, Jin X, Li J, Zhang M, Predicting pharmacodynamic effects through early drug discovery with artificial intelligence-physiologically based pharmacokinetic (AI-PBPK) modelling, Frontiers in Pharmacology, 15, 2024, 1330855.

[27] Marshall S, Macintyre F, James I, Krams M, Jonsson NE, Role of mechanistically- based pharmacokinetic/pharmacodynamic models in drug development: a case study of a therapeutic protein, Clinical pharmacokinetics, 45, 2006, 177-97.

[28] Maharaj AR, Barrett JS, Edginton AN, A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam, The AAPS journal, 15(2), 2013, 455-64.